Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 18/20 | 0.48 |
| ▸ | PDGFRA | P16234 | 9/20 | 0.48 |
| ▸ | PDGFRB | P09619 | 8/20 | 0.48 |
| ▸ | KDR | P35968 | 5/20 | 0.48 |
| ▸ | MET | P08581 | 5/20 | 0.48 |
| ▸ | FLT3 | P36888 | 3/20 | 0.48 |
| ▸ | KIT | P10721 | 8/20 | 0.46 |
| ▸ | AXL | P30530 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31352505 | 0.78 | CSF1R (0.54) | CSF1RPDGFRAPDGFRBKDRMET | |
| SCHEMBL3665924 | 0.78 | AXL (0.61) | CSF1RPDGFRAPDGFRBKDRMET | |
| SCHEMBL573860 | 0.77 | AXL (0.58) | CSF1RPDGFRAPDGFRBKDRMET | |
| SCHEMBL27299257 | 0.77 | CSF1R (0.51) | CSF1RPDGFRAPDGFRBKDRMET | |
| SCHEMBL572996 | 0.76 | CSF1R (0.50) | CSF1RPDGFRAPDGFRBKDRMET | |
| SCHEMBL29736898 | 0.76 | CSF1R (0.50) | CSF1RPDGFRAPDGFRBKDRMET | |
| SCHEMBL2919897 | 0.75 | AXL (0.60) | CSF1RPDGFRAPDGFRBKDRMET | |
| SCHEMBL2451490 | 0.75 | CSF1R (0.49) | CSF1RPDGFRAPDGFRBKDRMET | |
| SCHEMBL573861 | 0.75 | KDR (0.50) | CSF1RPDGFRAPDGFRBKDRMET | |
| SCHEMBL2444261 | 0.74 | CSF1R (0.50) | CSF1RPDGFRAPDGFRBKDRMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110189167-A1 | Methods and Compositions for the Treatment of Myeloproliferative Diseases and other Proliferative Diseases | DECIPHERA PHARMACEUTICALS, LLC | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110189167-A1 | Methods and Compositions for the Treatment of Myeloproliferative Diseases and other Proliferative Diseases | MCL1, NRAS, ABL1 | CSF1R 1244/4885PDGFRA 618/4885PDGFRB 664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.